Background: The molecular mechanisms behind diabetic neuropathy remains to be investigated.
Introduction
Diabetic neuropathy is a leading complication of diabetes characterized by progressive loss of peripheral nerve axons, leading to decreased sensation and pain. [1, 2] It tortures approximately 30% of patients with diabetes, and will finally occur in up to half of diabetic patients during the disease course. [3] Nerve damage usually occurs before symptoms and signs are clinically obvious. When the diabetic neuropathy is detected, irreversible damage often has already been caused. [4] It is a challenging task to prevent, slow, or reverse the progression of diabetic neuropathy. Therefore, it is of considerable significance to investigate the molecular mechanisms of diabetic neuropathy for prevention and treatment of the disease.
Omete et al [5] have suggested that inhibition of tumour necrosis factor (TNF) pathway might inhibit the progression of diabetic neuropathy in mice model. A latest study suggests that alterations in ion-channel function and energy metabolism depending on axon-glia crosstalk might also contribute to the development of diabetic neuropathy. [6] Moreover, Chen et al [7] have reported that nucleotide-binding oligomerization domain (NOD)-like receptor 3 (NLRP3) inflammasome activation mediated by ATP-P2X4 signaling might be implicated in diabetic neuropathyrelated inflammation. There is in vivo evidence that microRNA (miR)-29c knockdown or miR-27a knockdown compromises progression of diabetic nephropathy. [8, 9] Furthermore, Chien et al [10] have found that miR-21, miR-29a/b/c, and miR-192 are involved in pathogenesis of diabetic neuropathy and might be suggested as biomarkers of progression of diabetic neuropathy. Despite these achievements, the molecular mechanisms behind the diabetic neuropathy have not been fully elucidated.
Hur et al [11] have characterized the differentially expressed genes (DEGs) between patient samples with progressing diabetic neuropathy (fibers loss ≥500 fibers/mm 2 ) or nonprogressing diabetic neuropathy (fibers loss 100 fibers/mm 2 ), and unraveled that these genes are linked to inflammatory responses and lipid metabolism-related pathways. However, miRNAs are not targeted in their study. Using gene expression dataset (GSE24290) uploaded to NCBI GEO database, this study conducted a series of microarray analysis to shed light on development of promising drugs for prevention of diabetic neuropathy, and biological function of DEGs involved in progression of diabetic neuropathy. A weighted gene coexpression network analysis (WGCNA) [12] was used to search for gene clusters associated with diabetic neuropathy following identification of DEGs between progressing and nonprogressing diabetic neuropathy. Moreover, diabetes-related miRNAs and their target genes were predicted and mapped to the gene coexpression network for construction of a miRNA-gene network. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed for the genes in the miRNAs-target genes network. Additionally, potential drugs for prevention of the disease were also investigated, based on the identified DEGs.
Methods

Data preprocessing
It is a secondary study of gene expression dataset (GSE24290) downloaded from NCBI GEO database [13] (http://www.ncbi. nlm.nih.gov/geo/). The GSE24290 dataset included 18 nerve tissue samples from patients with progressing diabetic neuropathy (fibers loss ≥500 fibers/mm 2 ) and 17 nerve tissue samples from patients with nonprogressing diabetic neuropathy (fibers loss 100 fibers/mm 2 ). Preprocessing of the probe-level data in cell intensity (CEL) files was conducted using oligo package (Bioconductor, Seattle, Washington State, USA) of R 3.1.3 language, including conversion into expression measures, background correction, and quartile data normalization. [14] The platform of the data is GPL10526 (Affymetrix GeneChip Human Genome HG-U133 Plus 2 Array, Affymetrix, Santa Clara, CA, USA). No additional subjects were included, thus ethical approval and patient consent are not required.
Identification of DEGs and two-way hierarchical clustering analysis
Significant DEGs between progressing diabetic neuropathy samples and nonprogressing diabetic neuropathy samples were screened using Linear Models for Microarray Analysis package in R language. [15] The strict threshold was set at fold change (jlogFCj) ≥1.2 and P value < 0.05.
Weighed gene coexpression network analysis
The WGCNA package [12] in R software (GNU Project, Free Software Foundation, Boston, MA, USA) was applied to construct a weighted gene coexpression network. Briefly, the correlation efficient (S mn ) between gene m and gene n was calculated as follow: S mn = jcor (m,n) j. Second, the adjacency (a mn ) was calculated using power adjacency function: a mn ¼ power ðSmn;bÞ . Based on the scalefree behavior of the coexpression network, the weighted value (b value) was determined by linear correlation between the number of edges log (k), and the probability of finding a node with k edges P (k). The correlation coefficient between log (k) and log P (k) was set at ≥0.9. Subsequently, the adjacency matrix was converted into topological matrix.
Hierarchical clustering tree was built using hybrid dynamic shear tree method, with different branches corresponding to different gene modules. At least 30 genes were required for each module. The cut weight was set at 0.9. The module significance (MS) of each module was calculated as the average gene significance (GS) values of all genes in the module, with higher MS value indicating a closer connection of the module with the disease. GS value of the difference in the mRNA expression of each gene between progressing diabetic neuropathy and nonprogressing diabetic neuropathy was calculated using Student t-test.
Based on the GS values of all network modules, the top 3 modules were selected for construction of a gene coexpression network associated with diabetic neuropathy using heatmap.2 function of gplots package (Bioconductor) in R3.1.3. [16] 
Identification of diabetes-related miRNAs and prediction of target genes of miRNAs
The study searched for diabetes-related miRNAs using miR2-Diease database. [17] It is a monthly updated database, providing rich information concerning deregulated miRNAs in various human diseases. Its current version included 3273 curated associations between 349 human microRNAs and 163 human diseases by reviewing published papers. Subsequently, target genes of the diabetic-related miRNAs obtained were predicted using miRanda software [18] Computational Biology Center of Memorial Sloan, New York, USA) and TargetScan software [19] (www.targetscan.org, Whitehead Institute for Biomedical Research, Cambridge, MA, USA), which were commonly used tool for scanning target sites of miRNAs. These target genes were mapped to the gene coexpression network, and a miRNA-gene network was then constructed.
Identification of potential therapeutic small molecules
Connectivity map is a useful approach to mine connections among bioactive small molecules, which share an action mechanism, chemicals and physiological processes, and diseases and drugs. [20] With the help of Connectivity map (cmap), the DEGs were compared with the predefined signatures of drugs and drug-like small molecules, and ranked according to a connectivity score which corresponded to the relative similarity to the imported DEGs. The small molecules with P value <0.05 and jconnectivity scorej >0.8 were determined to be highly associated with diabetic neuropathy. The connectivity score ranged from À1 to 1. The score closer to À1 indicated that the drug had a stronger effect against the disease.
GO and KEGG pathway enrichment analysis
In order to unravel the biological function of the genes in the miRNA-gene network, GO function and KEGG pathway enrichment analysis was performed using Gostat software [21] (Bioconductor) and KOBAS software (KOBAS, Surrey, UK), [22] respectively.
Results
Identification of DEGs
Total 749 DEGs were screened between nonprogressing diabetic neuropathy and progressing diabetic neuropathy samples, including 370 upregulated DEGs and 379 downregulated DEGs.
WGCNA analysis and module selection
In order to guarantee the scale-free topology of the gene coexpression network, power = 6 was selected when the correlation coefficient between log (k) and log P (k) reached 0.9 for the first time (Fig. 1) . The constructed gene clustering tree (cut height = 0.9) was shown in Fig. 2 . Different modules were marked in different colors. All modules were with MS value >0.8 and MS P value <0.05. According to the MS value, top 3 modules ranked in descending order were selected, consisting of the blue module (156 DEGs), the brown module (55 DEGs), and the green module (47 DEGs) for further analysis (Fig. 3) .
Prediction of target genes of diabetes-related miRNAs
Using miR2Disease database, we obtained 3 miRNAs associated with diabetes: has-miR-377, [23] has-miR-216a, [24] and has-miR-217. [24] With the help of miRanda software and TargetScan software, the study predicted 1052 target genes of has-miR-377, 962 target genes of has-miR-261a, and 1025 target genes of hasmiR-217 (Table 1) .
Construction of the miRNA-target gene network
Has-miR-377, has-miR-216a, has-miR-217 and their target genes were mapped to the DEGs in the blue module, brown module, and green module. Consequently, a miRNA-target gene network was built, and shown in Fig. 4 . 
Selection of potential drugs against diabetic neuropathy
Based on the Connectivity map database, 5 small molecules with P value <0.05 and jconnectivity scorej >0.8 were selected to be potential drugs for diabetic neuropathy: desipramine, pirlindole, penbutolol, brinzolamide and pyridoxine ( Table 2 ). The connectivity score of desipramine was lowest (À0.935).
GO and KEGG pathway enrichment analysis
GO enrichment analysis revealed that the DEGs in the miRNA-target gene network were significantly related to 14 GO terms (Fig. 5A) . The most significant GO term was significantly enriched with 13 genes, such as adenosine A3 receptor (ADORA3), chemokine (C-X-C motif) ligand (CXCL) 9, bradykinin receptor B2 (BDKRB2), and complement factor H (CFH). CFH was a target gene of has-miR-216a. As for KEGG pathway enrichment analysis ( 
Discussion
Diabetic neuropathy is the most common complication occurred in diabetic patients. In order to unravel the molecular mechanisms underlying the progression of diabetic neuropathy, the study carried out WGCNA analysis to identify gene clusters associated with progression of diabetic nephropathy. The study further found that the DEGs in nonprogressing and progressing diabetic neuropathy were significantly enriched with several GO terms and KEGG pathways, such as inflammation, PPAR, and AMPK signaling pathways.
Increasing studies have demonstrated that inflammationrelated pathways play critical roles in the progression of diabetic nephropathy. [25, 26] The study confirmed the key role of inflammation, as evidenced by the finding that inflammation was the most significant GO term associated with DEGs in the miRNA-gene network. Hu et al [27] have found that PPARa expression is decreased in diabetic neuropathy rat model, and that PPARa overexpression inhibits diabetic neuropathy-related inflammation. Moreover, increasing evidence has suggested that PPARa and PPARg agonists may be promising agents for management of diabetic nephropathy. [28, 29] Similarly, the study also unveiled that PPAR pathway was the most significant signaling pathway enriched with several DEGs, including ANGPTL4, a target gene of has-miR-216a. ANGPTL4 is a member of the angiopoietinlike gene family produced from fat tissue and liver, involving in energy metabolism and insulin sensitivity. It is also a target of PPARs. It has been reported that ANGPTL4 overexpression modulates mitochondria function and methionine metabolic cycles in the liver of diabetic mice. [30] The study indicates that ANGPTL4 regulated by has-miR-216a and PPAR signaling pathway might participate in progression of diabetic neuropathy.
AMPK is an important enzyme in regulating cellular and whole-body energy homeostasis. [31] AMPK which plays critical roles in key metabolically relevant tissues is considered as an attractive drug target for diabetes. [32] The present study suggests that AMPK signaling pathway might be implicated in progression of diabetic neuropathy. Moreover, both AMPK and PPAR signaling pathways were significantly enriched with PPARG, SCD, CD36, and PCK1 in the present study. PPARG encodes PPARg protein. SCD gene encodes SCD protein, which is a critical enzyme involved in fatty acid metabolism. There is evidence that loss of SCD1 promotes glucose utilization in the heart of mice model. [33] CD36 is an integral membrane protein located on the surface of many cell types, participating in several process, such as inflammation and oxidative stress. [34] It has been reported that CD36 is involved in proximal tubular epithelial cell apoptosis of diabetic nephropathy. [35] Moreover, Shiju et al [36] have implied that soluble CD36 in plasma and urine might be a prognostic biomarker for diabetic neuropathy. PCK1 encodes phosphoenolpyruvate carboxykinase 1 protein, which is a key enzyme in gluconeogenesis. [37] Findings of this study indicate that PPARG, SCD, CD36, and PCK1 might participate in progression of diabetic neuropathy, partly by regulating AMPK and PPAR signaling pathways.
The study predicted that desipramine, pirlindole, penbutolol, brinzolamide, and pyridoxine might be promising agents for treatment of diabetic neuropathy. In consistence with this finding, it has been established that desipramine is effective in relieving pain in painful diabetic neuropathy. [38] However, the other 4 drugs have not been reported in management of diabetic neuropathy. In addition, there are some limitations in the study, including the single platform of dataset, the dataset is not sufficiently robust and the reproducibility has not been determined, and the sample size is small. In addition, the study only included microarray data analysis. Therefore, further experimental studies are needed to verify the findings of this study.
Conclusion
The study suggests that PPARG, SCD, CD36, PCK1, AMPK pathway, and PPAR pathway may be implicated in progression of diabetic neuropathy. The genes might be recommended as possible biomarkers for progression of diabetic neuropathy. Further experimental studies are necessary to verify the findings of this study.
